Literature DB >> 17304567

Hypoglutamatergic activity in the STOP knockout mouse: a potential model for chronic untreated schizophrenia.

Eiliv Brenner1, Ursula Sonnewald, Annie Schweitzer, Annie Andrieux, Astrid Nehlig.   

Abstract

In mice, the deletion of the STOP protein leads to hyperdopaminergia and major behavioral disorders that are alleviated by neuroleptics, representing a potential model of schizophrenia. The reduction of the glutamatergic synaptic vesicle pool in the hippocampus could reflect a disturbance in glutamatergic neurotransmission in this model. Here we examined potential disturbances in energy metabolism and interactions between neurons and glia in 15-week-old STOP KO, wild-type, and heterozygous mice. Animals received [1-(13)C]glucose and [1,2-(13)C]acetate, the preferential substrates of neurons and astrocytes, respectively. Extracts from the whole forebrain and midbrain were analyzed by HPLC, (13)C and (1)H NMR spectroscopy. Amounts and labeling of most metabolites were unchanged. However, glutamine concentration and amount of [4,5-(13)C]glutamine derived from [1,2-(13)C]acetate significantly decreased by 17% and 18%, respectively, in STOP KO compared with wild-type mice. The amount of [4-(13)C]glutamate was decreased in STOP KO and heterozygous compared with wild-type mice. gamma-Aminobutyric acid labeling was not influenced by the genotype. Because STOP-deficient mice have a lower synaptic vesicle density, less glutamate is released to the synaptic cleft, leading to decreased stimulation of the postsynaptic glutamate receptors, reflecting increased glutamine metabolism only in the vicinity of the postsynapse of STOP KO mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17304567     DOI: 10.1002/jnr.21200

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  15 in total

1.  Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

Authors:  Kosuke Kajitani; Michael Thorne; Michel Samson; George S Robertson
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

2.  Reduced Glutamate Release in Adult BTBR Mouse Model of Autism Spectrum Disorder.

Authors:  Hongen Wei; Yuehong Ma; Caiyun Ding; Guorong Jin; Jianrong Liu; Qiaoqiao Chang; Fengyun Hu; Li Yu
Journal:  Neurochem Res       Date:  2016-08-19       Impact factor: 3.996

Review 3.  Astrocyte Bioenergetics and Major Psychiatric Disorders.

Authors:  Ivan V Maly; Michael J Morales; Mikhail V Pletnikov
Journal:  Adv Neurobiol       Date:  2021

4.  New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia.

Authors:  Avia Merenlender-Wagner; Zeev Shemer; Olga Touloumi; Roza Lagoudaki; Eliezer Giladi; Annie Andrieux; Nikolaos C Grigoriadis; Illana Gozes
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

5.  Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice.

Authors:  David Delotterie; Geoffrey Ruiz; Jacques Brocard; Annie Schweitzer; Corinne Roucard; Yann Roche; Marie-Françoise Suaud-Chagny; Karine Bressand; Annie Andrieux
Journal:  Psychopharmacology (Berl)       Date:  2009-11-21       Impact factor: 4.530

6.  Deletion of the STOP gene, a microtubule stabilizing factor, leads only to discrete cerebral metabolic changes in mice.

Authors:  Ryosuke Hanaya; Estelle Koning; Arielle Ferrandon; Annie Schweitzer; Annie Andrieux; Astrid Nehlig
Journal:  J Neurosci Res       Date:  2008-03       Impact factor: 4.164

7.  Disruptions of Sleep/Wake Patterns in the Stable Tubule Only Polypeptide (STOP) Null Mouse Model of Schizophrenia.

Authors:  Maxine F Profitt; Samuel Deurveilher; George S Robertson; Benjamin Rusak; Kazue Semba
Journal:  Schizophr Bull       Date:  2016-03-02       Impact factor: 9.306

Review 8.  Glucose Transporter Type I Deficiency (G1D) at 25 (1990-2015): Presumptions, Facts, and the Lives of Persons With This Rare Disease.

Authors:  Juan M Pascual; Gabriel M Ronen
Journal:  Pediatr Neurol       Date:  2015-08-10       Impact factor: 3.372

9.  Altered circadian activity and sleep/wake rhythms in the stable tubule only polypeptide (STOP) null mouse model of schizophrenia.

Authors:  Samuel Deurveilher; Kristin Robin Ko; Brock St C Saumure; George S Robertson; Benjamin Rusak; Kazue Semba
Journal:  Sleep       Date:  2021-04-09       Impact factor: 5.849

10.  Reduced expression of STOP/MAP6 in mice leads to cognitive deficits.

Authors:  Julien Volle; Jacques Brocard; Mohamed Saoud; Sylvie Gory-Faure; Jérôme Brunelin; Annie Andrieux; Marie-Françoise Suaud-Chagny
Journal:  Schizophr Bull       Date:  2012-09-20       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.